Prosecution Insights
Last updated: November 20, 2026

Jieun Ham, USPTO Patent Examiner

Listed by the USPTO as HAM, JIEUN

Tech Center 1600 • Art Units: 1600 1643 1645 1652

This examiner grants 46% of resolved cases

Analysis

HAM, JIEUN is assigned to Tech Center 1600 and Art Unit 1600. The profile records 11 resolved cases, a 45.5% allowance rate, and a 1079-day median time to allowance. Interview lift is 0.0%. The small resolved-case record limits the strength of any broad inference, but it shows an observed allowance rate below half and no measured interview association with allowance.

The listed companies are Board of Regents of the University of Texas System, Korea Institute of Science and Technology, and Korea Advanced Institute of Science and Technology. The listed firms are NORTON ROSE FULBRIGHT US LLP, pH IP Law, and Apex Attorneys at Law, LLP. These names may help identify relevant prosecution experience. Counsel should emphasize written claim development and prepare for a lengthy timeline, without assuming that an interview will materially change the outcome.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

45.5%
Allow Rate
-14.5% vs TC avg
45
Total Applications
+0.0%
Interview Lift
1079
Avg Prosecution Days
Based on 11 resolved cases, 2023–2026

Rejection Statute Breakdown

0.7%
§101 Eligibility
16.9%
§102 Novelty
33.8%
§103 Obviousness
28.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18300169 PHARMACEUTICAL COMPOSITIONS OF THERAPEUTIC PROTEINS AND METHODS OF USE Final Rejection Hoffmann-La Roche Inc.
18039071 EXOSOMES EXPRESSING RSVF AND USE THEREOF Final Rejection KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
17773658 SMALL LIPID NANOPARTICLES, AND CANCER VACCINE INCLUDING SAME Non-Final OA KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
18565831 METHODS OF USING ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING T CELLS Non-Final OA Regents of the University of Minnesota
18202066 MAP KINASE PATHWAY TARGETS FOR THE TREATMENT OF MARFAN SYNDROME Final Rejection The Johns Hopkins University
18491850 EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF Non-Final OA Merck Sharp & Dohme LLC
18546682 Inhibition of SLC4A4 in the Treatment of Cancer Final Rejection KATHOLIEKE UNIVERSITEIT LEUVEN
18699702 ENGINEERING NK CELLS WITH A CAR CONSTRUCT WITH OPTIMAL SIGNALING Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
17904473 CHIMERIC SCAVENGER RECEPTORS TARGETED TO PHOSPHORYLATED TAU (PTAU) AND USES THEREOF Non-Final OA Board of Regents, The University of Texas System
18698343 TREATMENT OF LUPUS Non-Final OA ASTRAZENECA AB
18308778 MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND CD123 Non-Final OA SANOFI
18577912 DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF MYASTHENIA GRAVIS Non-Final OA Alexion Pharmaceuticals, Inc.
18549459 METHOD FOR TREATING CANCER BY USING ANTIBODY-DRUG CONJUGATE AND USE Final Rejection SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Jieun Ham's allowance rate?

45.5% of resolved applications examined by Jieun Ham were allowed (11 resolved cases), compared with 36.5% across Art Unit 1600 over the last five years.

Does an interview help with examiner Jieun Ham?

This examiner's interview lift is +0.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Jieun Ham take to allow a patent?

Applications allowed by Jieun Ham took 1,079 days on average from filing to allowance.

Which art unit does examiner Jieun Ham work in?

Jieun Ham examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month